2+ hour, 18+ min ago   (260+ words) In the final part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, explains how understanding premiums, coverage trade-offs, and HSAs remains a major challenge for patients'and for…...

1+ week, 6+ hour ago   (344+ words) The company will participate in the Trump administration's direct-to-patient drug platform, while committing $100 billion to US R&D and manufacturing. AbbVie has reached a deal with Trump administration to join TrumpRx, a direct-to-patient platform with a goal to drug prices…...

2+ week, 1+ day ago   (388+ words) In the third part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, explains as medical inflation persists and benefit designs strain under rising drug spend'especially GLP-1s'employers are reaching the limits of what they…...

2+ week, 2+ day ago   (300+ words) In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, points out that a Medicaid spending tightens and ACA subsidies lapse, reduced public coverage is driving spillover effects'shifting costs to hospitals, employers,…...

2+ week, 2+ day ago   (447+ words) In the first part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, discusses how from GLP-1 adoption to specialty drugs, behavioral health utilization, and hospital consolidation, multiple forces are reshaping employer-sponsored healthcare costs'and pushing…...

1+ mon, 1+ week ago   (491+ words) The entrepreneur urges the Trump administration to eliminate costly FDA generic drug fees, part of a broader push to scale domestic production, address shortages, and challenge PBM-driven pricing models. Mark Cuban'has been encouraging the Trump administration to waive the hundreds…...

1+ mon, 3+ week ago   (541+ words) As the federal government prepares to release newly negotiated Medicare drug prices, weight-loss blockbusters Ozempic and Wegovy remain in the spotlight, while CMS advances a model to cut Medicaid spending and broaden access to affordable treatments. Later this week, the…...

2+ mon, 7+ hour ago   (655+ words) When intelligence flows across clinical, access, and engagement channels, commercialization shifts from reactive to predictive, giving teams the real-time edge to win in a fast-moving market. The era of commercialization isn't about who has the most data. It's about who…...

2+ mon, 3+ week ago   (298+ words) Nine drugs from leading manufacturers will participate in HRSA's new 340B rebate model pilot program, set to begin in 2026, which aims to evaluate a rebate-based framework for future drug pricing models amid ongoing industry litigation. The US Health Resources and Services…...

2+ mon, 4+ week ago   (264+ words) First in a three-part series. Next up: what is DTP and who benefits from it? The prize is significant: higher dispense rates, stronger adherence, richer real-world data, and a patient experience that builds - not erodes - brand trust. In a system…...